Search results
Author(s):
Christie Ballantyne
Added:
4 weeks ago
AHA Scientific Sessions 2025 - Dr Christie Ballantyne (Baylor College of Medicine, Houston, TX, US) discusses findings from the CORALreef HeFH trial, examining the efficacy and safety of enlicitide decanoate, an oral PCSK9 inhibitor, in adults with heterozygous familial hypercholesterolemia.This Phase 3, randomized, double-blind, placebo-controlled study evaluated 303 participants with…
View more
SGLTi and GLP-1 in HF
Author(s):
Jose Lopez
,
Tracy Makuvire
,
Jonathan D Davis
,
et al
Added:
6 months ago
Article
Author(s):
Frederick Raal
Added:
2 years ago
ESC 23 — Prof Frederick Raal (University of the Witwatersrand, Johannesburg, SA) outlines the late-breaking results from the LIBerte-HeFH study (NCT04797104).
The phase III LIBerte-HeFH study (LIB Therapeutics LLC) aimed to assess the effectiveness of PCSK9-inhibitor Ierodalcibep (LIB003) in reducing low-density lipoprotein cholesterol (LDL-C) in 300mg doses administered subcutaneously in…
View more
Lifestyle Modification after PCI
Author(s):
Nicholas Nguyen
,
Katherine C Michelis
Added:
11 months ago
Article
Author(s):
Added:
4 weeks ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview…
View more
Author(s):
Zara Latif
,
Tracy Makuvire
,
Sarah Schroeder
,
et al
Added:
1 week ago
Kieran Docherty
Research Area(s) / Expertise:
Job title: Clinical Lecturer (Institute of Cardiovascular & Medical Sciences)
Author
Author(s):
Erin A Bohula
,
Harriette Van Spall
Added:
3 weeks ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9…
View more
Author(s):
Andrew Wang
Added:
4 weeks ago
AHA Scientific Sessions 2025 – MAPLE-HCM responder analysis shows aficamten monotherapy led to greater treatment effect when compared to metoprolol monotherapy.Dr Andrew Wang (Duke University Medical Center, Durham, NC, US) presents a responder analysis from the MAPLE-HCM trial (NCT05767346), examining clinical responses to aficamten monotherapy versus metoprolol in patients with obstructive…
View more
Antoni Bayés-Genís
Job title: Head of the Cardiology Department
Author